| |
Delcath Signs First Partner Agreement in Asia
Tue 7:15 am ET (PR Newswire)
Delcath Systems, Inc. , a medical technology company testing its proprietary treatment system for primary and metastatic cancers to the liver, announced today the signing of its first research, distribution, sales and marketing agreement for its Percutaneous Hepatic Perfusion System . The agreement grants Chi-Fu Trading Co., Ltd. the exclusive right to market and sell the Delcath PHP System in Taiwan for hepatic malignancies and infectious disease upon Taiwan Food and Drug Administration approval, and any other approved use, with a conditional option for Singapore.
|
| | |
Locate Industry by Company
|
| Market Capitalization: | 17B | | Price
/ Earnings: | 34.5 | | Price
/ Book: | 19.9 | | Net
Profit Margin (mrq): | 8.0% | | Price
To Free Cash Flow (mrq): | -49.3 | | Return
on Equity: | 13.3% | | Total
Debt / Equity: | 0.0 | | Dividend
Yield: | 2.5% |
|
